Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to new results.
Read Original Article: Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis »
